2 studies on Cd36 ligand mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
These findings identify GHRP-6 azapeptide analogs as a promising new class of therapeutics for atherosclerosis by selectively targeting the `CD36` receptor. The ability to not only halt plaque progression but also reg…
**The antioxidant and anti-inflammatory profile of GHRP-2 does not automatically translate into structural plaque regression** — a critical distinction for anyone considering this peptide as a cardiovascular adjunct. …